DEFA14A

Set forth below are the transcript and presentation made by management of Cytyc at the NASDAQ 19^th Investor Program on June 19, 2007 at 5:00 p.m., London time (12:00 noon Eastern).

Male Speaker: We are very pleased to have Cytyc with us. We have Pat Sullivan, President and CEO. I am introducing the company on behalf of David Lewis also on our MedTech Team in New York who covers this stuff, but was unable to join us today. So, with that, I will turn it over to Pat. Hey Pat.

Patrick J. Sullivan: Thank you, and good afternoon. It is a pleasure being with all of you here in London. It is quite a beautiful day today. What I would like to do this afternoon is provide you with an overview of Cytyc Corporation as well as some comments on the merger that we just announced, but before I do, since our lawyers require, I need to take you through some forward-looking statements. This is a record, by the way. These are seven forward-looking statements. So, I will just glance through them. There are forward-looking statements in this presentation. I would advise our investors to please refer to our 10-Ks and 10-Qs on file with the SEC regarding forward-looking statements regarding Cytyc as well as forward-looking statements regarding the Hologic and Cytyc transaction as well as important information for shareholders as we look at the upcoming shareholder meetings, etc. Please visit our website for our 10-Ks and 10-Qs.

So, first I would like to talk a little bit about Cytyc as a stand-alone and then address really the opportunity with Hologic. We are a company based in Boston, Massachusetts. Last year, we did about $600 million in revenue and have continued to deliver a 20% topline and 20% bottomline growth specifically dedicated to women’s health. I mean, all of our products focus on women’s healthcare, particularly gynecological health. So, we have embarked on a strategy over the last couple years to continue that growth, to grow our existing businesses as well as acquisitions to allow us to continue growth, and I think one of the challenges that we as well as many other growing companies, improving the PBIT margins as well as attracting talent into the organization to really fuel and sustain our growth.

If you look at Cytyc in 2003, we were actually founded in 1987, the principle product being the ThinPrep Pap Test, and until 2003, we were a one-product company. Our product was the ThinPrep Pap Test, which is the replacement for the conventional Pap smear for screening women for cervical cancer. And so, what we did differently was we rather than smearing the cells in the slide, we had the physician place the sample in a vial of solution such as I have here in my hand, and basically, this was the only product that the company had until 2003.

So, we had developed about a $300 million business, 90% of it inside the United States and 10% outside United States focused specifically on replacing the conventional Pap smear. In 2004, we really started to diversify. We acquired a company called Novacept

in California that put us into providing a very exciting new product for treating women with abnormal uterine bleeding called NovaSure, and we got into the surgical side of the business, again women’s gynecological health, and then further acquisitions in 2005, put us in breast care with our MammoSite breast care product, and then in 2007, earlier this year, we just recently announced the acquisition of Adiana, which is a permanent sterilization product as well as our Adeza product, which is a diagnostic product for determining whether a woman is at risk for pre-term delivery. So, all of our products were going off a base about $300 million in 2003, doubling by 2007.

They give me one-on-ones all day and I have exercised my voice and then I lose it at the presentation time.

So, this gives you the list of the various products NovaSure and our surgical products, MammoSite Radiation Therapy, the Adiana product is a product for permanent sterilization as well as another product for endometriosis called Helica that we currently have in the pipeline.

Our diagnostics businesses, the flagship product, the ThinPrep Pap Test, the imaging system, which is an additional diagnostic product on top of that as well as two additional products, the Cellient System, which is a product for laboratory customers as well as the Fetal Fibronectin Test for determining a woman’s risk of pre-term delivery. We also market all of our products in the US in separate divisions, surgical and diagnostics. Internationally, they are in one division, international group markets, all of the products.

To start off with surgical products, this is the NovaSure product, this is the one we acquired in 2004, a 4-minute outpatient procedure for treating women that have abnormal uterine bleeding during their menstrual cycle. It is the best-in-class product, requires no pretreatment in order to perform the procedure. It is typically done under conscious sedation and recovery is less than an hour. When we acquired the product in the year 2003, they did $38 million in revenue, in ‘04 we did $75, and we are going up by $50 million in revenue each and every year. This year we are expected to do somewhere around $225 million in top-line revenue with our NovaSure device becoming and really is the best-in-class product.

When you look at the opportunity for treating women for abnormal bleeding, it is quite large. On the very left-hand side of the graph, the total number of patients that are affected by this disorder is about 7 million, but unfortunately, only about 2.5 million of those women actually seek treatment. It turns out that about 1.8 million of those women end up going on oral contraceptives or some sort of hormonal therapy to try to mitigate the menstrual flow, but many undergo a hysterectomy, dilation or curettage or the other category that has just emerged, the GEA category called global endometrial ablation. So, today the market has about 300,000 procedures and it is growing at about 50,000 procedures per year over the last several years.

When you look at NovaSure compared to the other products, we compete with some rather well known companies J&J has a product called Therma Choice, Boston Scientific has a product called Hydro ThermAblator, American Medical Systems has another product that uses freezing technology to ablate the uterus. All of those products require some sort of pre-treatment; either a dilation a curettage or a single or double dose of Lupron. Lupron is a drug that thins the endometrial lining that makes the ablation occur more effectively. In the case of NovaSure, there is no pre-treatment required. The woman could come in in the morning, be identified and be treated in the afternoon. The other significant advantage is one of time. In the OR it takes about a half hour, or the outpatient procedure takes about a half an hour. In the case of NovaSure from start to finish it’s about 4 minutes. In the case of all the other competitive products it takes about 10 minutes to apply the [ ] and in the case of NovaSure it’s literally 90 seconds. So, from start to finish, very quick, very safe and the most effective product on the market. When you look at comparing all of these devices to rollerball ablation, NovaSure is head and shoulders the market leader as well as the best-in-class product.

If you look at the overall market opportunity when you look at just the global endometrial ablation procedures, last year again about 300,000 procedures, we’re about 60% of the market, on a dollar value basis about 70% of the market. But when you look at the women that are undergoing hormone therapy or the women that suffer from this disorder we are barely scratching the surface with 9% and 3%, respectively. So we think we have a tremendous market opportunity to further expand this market. In addition, we are taking this product for elective use, so women who don’t suffer from abnormal bleeding but just have normal periods but want to eliminate this issue in their lives. We are conducting a clinical trial that we expect to start this year to allow us to market the product for elective use, and that in and of itself is about a $1 billion market opportunity.

The second product that we have in our surgical products division is our MammoSite radiation therapy product. And this is a method by which you provide for radiation therapy post-lumpectomy. So, today a woman that has breast cancer would go in and often times a lumpectomy would be performed or only a certain portion of the breast would be removed and she would go on to whole breast radiation. The reason you provide whole breast radiation is because, without it the woman’s risk of recurrence of breast cancer in that same breast at the same site is about 30-40%. If you provide radiation therapy post-lumpectomy, her risk of developing a recurrent breast cancer drops to about 5%. So the standard on the market today is to provide whole breast radiation from the outside in to basically provide radiation to the tumor bed to prevent recurrence. This device has a balloon on the end of it, so at the end of this device is a balloon catheter. This is actually inserted into the site of the lumpectomy in the same place where the tumor was removed, and then what happens is you thread a radiation source through this catheter and you irradiate the cancer or the cancer site from the inside out. And rather than providing this whole breast radiation is 30 days of therapy, in the case of the MammoSite device, it’s 5 days of therapy. So the major benefit for the woman and the physician is you can reduce her risk of developing breast cancer by providing radiation therapy but you’re taking the time of therapy down from 30 days down to 5

days. In the U.S. there is a big problem with women becoming compliant with the radiation therapy. Many women either opt for a mastectomy because it is such a hassle to go get whole breast radiation, or they just don’t do it at all and then of course you have the 30-40% chance of cancer recurrence. So we think this is a great market opportunity for us. When you look at the overall size of the market as 270,000 breast cancer patients in the United States and then you back down those patients for whom MammoSite is really not appropriate. Where the woman would have a mastectomy is obviously not a candidate as well as women that have a large tumor or who have had lymph node involvement as well as women who have relatively small breasts would not be candidates, so you get the overall market size being about 125,000 procedures on an annual basis. Today, we are about 10% penetrated into that market opportunity, so tremendous growth on our breast cancer product offering. And this is one, when I talk about Hologic, where there is very interesting fit between this product and all of the Hologic products.

The other product that we acquired earlier this year is called Adiana. It’s a permanent sterilization device that is used as an alternative to tubal ligation. And basically what it is is a silicone matrix that is inserted into the fallopian tubes of the woman that prevents the eggs obviously from coming through the fallopian tubes into the uterus. We are in the FDA process. Over the next several weeks we expect to submit this application to the FDA and expect approval in the first quarter of next year. It is extraordinarily complimentary to our NovaSure endometrial ablation system. All women who have had a NovaSure procedure, or any endometrial ablation procedure for that matter, need to be on some sort of contraception, and this product would be marketed and sold by our existing sales force, of which we have about 100 directly to the same physicians that are doing NovaSure, so we think this is a great fit. It is a $1 billion market opportunity, and thanks to a competitor in the market, reimbursement is established on a nationwide basis.

The overall summary of the surgical products, it is our fastest growing in excess of 30% growth year over year, NovaSure being the best-in-class product, the elective use of that product being a $1 billion market opportunity. MammoSite becoming the standard of care versus whole breast radiation in breast cancer radiation therapy. And our hysteroscopic radiation product, Adiana being a significant growth driver in 2007 and beyond, 2008 and beyond.

If you move to diagnostic products, this is the products on which the company was founded back in 1996. The flagship product is the ThinPrep Pap Test. We are the market leader in liquid-based cytology, with about 70% market share. Our imaging system is a diagnostic methodology to better and more efficiently review the ThinPrep slides at the laboratory. Now we have additional products, with the FullTerm product for our OB/GYN sales force for identifying women at risk for pre-term delivery, as well as another product for our laboratory sales force called Cellient.

When you look at the overall superiority of the ThinPrep system, the conventional Pap smear has been around since the late ‘40s and it had done a reasonable job of screening

women for cervical cancer. There had really been no improvement until the ThinPrep Pap Test was approved in 1996. So, this graph here in the lower right hand corner shows the market share advancement of ThinPrep; 4%, 6%, 15% and today we are pretty level at about 70% market share, and I would point out by the way this is the same growth pattern that the MammoSite device is on as well. If you look at the reduction in the incidents of cervical cancer in the United States from 1996 through 2005 there has been a 28% reduction in the incidents of cervical cancer, due to, we believe or one of the reasons for that reduction is the widespread adoption of the ThinPrep Pap Test. It is significantly better than the conventional Pap smear for the detection of all lesions as well as all precancerous lesions. The ThinPrep imaging system provides for incremental benefit from both a productivity as well as an accuracy perspective. And we have the ability to do additional tests out of the ThinPrep vial. So, if you think of this as you touch the patient once and you can sample for not only a better Pap test, but you can test the patient for Chlamydia, Gonorrhea, HPV and other STDs as well. So, one vial, many solutions, many tests can be performed using our ThinPrep technology.

[beeping] I hope that wasn’t the timer. In any event, the imaging system is a computer system that provides for automated screening of the ThinPrep Pap Test. It basically helps the human identify areas of interest or cells of interest that the imager picked up that could be cancerous, and then the human makes the final decision as to whether that cell or that particular sample is either abnormal or normal. It significantly improves the accuracy of the screening and also improves the laboratory economics because there is additional reimbursement provided as well as a reduction in labor cost. So, it is not only more efficient, but it is also much more effective. It protects our market share with ThinPrep because our imaging system can only be used with the ThinPrep Pap Test and vice versa, and a significant increases use in the precursor to cancer called high-grade lesions using our technology versus the conventional.

I would point out that in the UK and since that’s where we are today, the National Health Service is basically converting the entire UK system forward to liquid-based cytology. They started this program in 2003, and are going through 2008, to convert all of the conventional Pap smears in the UK to liquid-based cytology, and we believe in the UK we will be essentially about 70% of the overall market within the UK. It is the only country in the world that is converting the entire screening system to the new and more efficient and effective technologies.

When you look at the imaging system in the US, as I mentioned you have to use the ThinPrep Pap Test, when you look at the number of slides, the slides that are going through and being imaged it was 40% at the end of the fourth quarter, it was about 46% at the end of the first quarter. So, we are making significant progress in making the imaging system become the standard of care for screening ThinPrep slide.

The Cellient System, I will not spend a lot of time on this. This is another methodology, another product that we will be marketing to our laboratory customers, that will take residual material that is left behind in the ThinPrep vial and allow the laboratory to do

additional tests on tissue samples that they would not otherwise be able to do from a ThinPrep sample. So, this is a product we currently have in beta-site testing. It is about a $100 million market opportunity for us in the US and another $100 million worldwide.

The Fetal Fibronectin Test came to us from Adeza. It is, as I mentioned identifies women at risk for pre-term birth. It is FDA approved. They did about $45 or so million last year in revenue. It is about a $500 million market for us worldwide, and it is now in the hands of our sales force, and we expect to do somewhere between $45 and $50 million in incremental revenue over the balance of the last three quarters of this year, taking our total revenue up to around $750 million for the year.

So, when you look at diagnostics, we have the ThinPrep Pap Test. The Pap test itself is relatively flat. We do about nine million tests on a quarterly basis. The imaging system is growing quite nicely. The international opportunity for this product is significant, a 100 million tests worldwide. It is the standard. We have done over 250 million tests since the product was approved. The imaging system is making great advancements not only in the US, but there are a number of systems in the UK and throughout Europe that we think will become the standard here as well, and we have a number of other products that we think will continue the growth on our diagnostics products side.

So, when we look at international, we are a company that is operating in over 20 different countries. We are direct in all of Europe. Our headquarters is here in the UK. Direct presence in France, Spain, Germany, Switzerland, Italy, as well as Hong Kong and Australia, and we operate our distributor in China through our Hong Kong office. About 170 people worldwide and about 12% of our revenue and it comes from international and it has been growing quite nicely with a 30% compounded annual growth rate year over year, and we continued. We believe that this trend will continue. It is a huge market opportunity. When you think of the Pap test outside of the United States, there is 44 million Pap tests done in Europe, Asia Pacific, 30 million of the 48 million tests are done in China and that is a significant growth opportunity for us as well as another 22 million in the rest of the world.

So, now, I would like to speak specifically, a little bit of the details, on the Hologic-Cytyc merger that was announced toward the end of May that we are very excited about. We believe that this really creates for the first time a global leader in women’s healthcare. If you search in all of the companies out there with the exception of pharmaceuticals, I think that the Cytyc-Hologic combination will create the premier women’s leading healthcare company with very rapid growth.

So, when you look at the strategic graph rationale, we think that it does expand significantly the product portfolio of both companies. There are two very strong companies coming together to create even a stronger company. We think that there is a significant ability to leverage the OB/GYN sales channel that we are very prominent in as well as direct cross-selling synergies particularly on the breast side, the international as well as the discovery osteoporosis screening product. When you look at the combined

strengths, we will become a financial powerhouse with close to $500 million in EBITDA, a very significant cash flow generation, proven management teams that have been around for a long period of time, and I have been at Cytyc for about 16 years, Jack has been at Hologic for about seven or so, and I think we have both demonstrated an ability to integrate acquisitions in a meaningful way to provide for value for investors.

When you look at the comprehensive healthcare platform and you think about breast care, mammography being the discovery or the screening for breast cancer, the Selenia product is an absolute best-in-class product in digital mammography and is taking off, growing extraordinarily fast, tie that together with the stereotactic biopsy, the Suros biopsy systems, the MammoSite Radiation Therapy system, you have a whole suite of products now that are focused principally on women’s breast cancer and breast care. When you tie that together with the gynecological life products, the ThinPrep Pap Test, the NovaSure device for abnormal bleeding, contraception, you have a full suite of best-in-class products for marketing to breast surgeons and OB/GYNs and really a significant suite of products that are best-in-class for women’s health. If you look at the various markets on which we will compete, breast cancer, cervical cancer, menorrhagia, contraception, pre-term labor, endometriosis, the products are number one in each and every one of those categories. We are the market leader in virtually each and every product category in which we compete. Large market opportunities, billion dollar plus market opportunities, and when you add together the combined strengths of the R&D and the sales and marketing organization, we think we will have a very significant women’s healthcare company.

The financial rationales is also, I think, quite strong. We have increased scales with diversification of the revenue stream. If you take the last quarter annualized of EBITDA, it is $436 million, significant revenue and cost synergies as well. We believe $75 million on revenue and about $25 million on cost over the next three years. At the announcement, we talked about $0.10 accretive to the adjusted earnings per share and significantly more accretive thereafter, and when you look at the debt repayment, part of this will be in debt and part in cash and stock. The debt repayment is because the cash flow is very fast.

Both companies are about the same size, now a little over $700 million in revenue. Their margins are about 46%. Ours are around 75%. Combine the two companies together; you have a last-quarter annualized revenue of $1.4 billion, a 60% gross margin and again a $436 million in EBITDA, so I think a very strong financial performance.

So, we think that these two companies coming together really will create a very comprehensive women’s healthcare company focused specifically on women’s health. We will have expanded commercial capabilities across both organizations where we will have expanded sales coverage. International, the two companies together will have significant opportunities. They use principally a distributor model with 25% of the revenues, we are a direct model, with about 12% of our revenues coming from international. And we will have a platform when you think about breast surgery or

radiation oncology, OB/GYN, there are many opportunities that we think we will be able to layer into that combined strength of the two organizations to really provide better diagnosis, screening, and therapeutics for women’s healthcare.

So, with that I guess what I would like to do is take a drink of water and then ask for some questions or if you have questions now.

Patrick J. Sullivan: I have five minutes on the shot-clock, well four and a half. I think one of the things that I would argue that the market probably does not completely understand or it does not buy into yet is the sales synergy of the OB/GYN channel, and there are really direct sales synergies principally on breast, international and the osteoporosis product, so those products can be sold by the combined sales force. In the case of breast biopsy, the sales product, that they have a handheld device that they now market only to the radiologists as a perfect fit with the breast surgeries. So, we have 58 breast surgery specialists that call on breast surgeons and radiation oncologists selling our MammoSite product. That product can be easily sold by our sales force, that is number one. Number two, we have an international distribution system that we think will be able to capture some of the margins that we are otherwise giving up to the international distributors, and three, the osteoporosis product. It is about a $60 million product for Hologic today that is sold by 12 sales people and through PS&S, Physician Sales and Service in the US. It is a distribution company for physicians’ offices. Those are the direct synergies. The one that I would call the indirect synergy is the ability of our OB/GYN sales force to influence the OB/GYN to send their patients to centers, mammography centers, that have the Hologic digital mammography product. When a women goes in for her well woman visit, she has a pelvic examination, a Pap test as well as a clinical breast examination, and when she leaves the office, the doctor tells her ‘Make sure you go get your mammogram’. 87% of physicians in the United States, OB/GYNs, refer women to the radiologist for mammograms. Report comes back to the OB/GYN as to what the result of that specific mammography was. And we have done this with the ThinPrep Pap Test where we do not sell this device, we do not sell this product to the OB/GYN, we market it to the OB/GYN, we do not sell it. We sell it to the laboratory. We do not sell the imaging systems to the OB/GYN. We market it to the OB/GYN to have them check the box to get the laboratory to do it, and over the years Cytyc has developed a reputation of really moving markets and essentially in some respects forcing the laboratories to provide the ThinPrep Pap Test in 1996, when there was no demand for it. We created the demand for that test, and we think we will be able to have a significant impact in the use and utilization of digital mammography with our OB/GYN sales force. So, that is what I would classify you have got your direct synergies with pure-play products into existing sales channel and a more indirect sales presence.

So, there are about 40 million mammograms done in the United States this year. If you look at digital mammography, the most recent numbers are that there has only been about 19% conversion to digital mammography and Hologic has, I think about half of that. So, we think we are going to be able…and the parallels between the ThinPrep Pap Test being a better test and digital mammography being a better mammogram, the parallels between cervical cancer and breast cancer are very simple and easy for our sales force alone to market OB/GYN.

Male Speaker: Yeah, it has worked on the ThinPrep side, so look forward to seeing how it works on the Hologic side.

Male Speaker: With that I think we are out of time, and I would like to thank Pat again for joining us. Have a good evening.

Disclaimer Regarding Forward-Looking

Statements

Forward-Looking

Statements

Regarding

Cytyc

Investors

are

cautioned

that

statements

this

presentation

which

are

not

strictly

historical

statements,

including,

without

limitation,

Cytyc's

future

financial

condition,

operating

results

and

economic

performance,

and

management's

expectations

regarding

key

customer

relationships,

future

growth

opportunities,

product

acceptance

and

business

strategy,

constitute

forward-looking

statements.

These

statements

are

based

current

expectations,

forecasts

and

assumptions

Cytyc

that

are

subject

risks

and

uncertainties,

which

could

cause

actual

outcomes

and

results

differ

materially

from

those

statements.

Risks

and

uncertainties

include,

among

others,

the

successful

integration

acquired

businesses

into

Cytyc's

business,

dependence

key

personnel

and

customers

well

reliance

proprietary

technology,

uncertainty

product

development

efforts

and

timelines,

management

growth,

product

diversification,

and

organizational

change,

entry

into

new

market

segments

domestically,

such

pharmaceuticals,

and

new

markets

internationally,

risks

associated

with

litigation,

competition

and

competitive

pricing

pressures,

risks

associated

with

the

FDA

regulatory

approval

processes

and

healthcare

reimbursement

policies

the

United

States

and

abroad,

introduction

technologies

that

are

disruptive

Cytyc's

business

and

operations,

the

potential

consequences

the

restatement

Cytyc's

Disclaimer Regarding Forward-Looking

Statements (continued)

financial statements for the period 1996 through 2002, relating to certain employee stock

option

exercises, including the impact of the expected any regulatory review or litigation

relating to such matters, the impact of new accounting requirements and governmental rules

and regulations, as well as other risks detailed in Cytyc's filings with the SEC, including those

under the heading "Risk Factors" in Cytyc's 2006 Annual Report on Form 10-K/A and

Adeza's 2006 Annual Report on Form 10-K, all as filed with the SEC.

Cytyc

cautions

readers

not

place

undue

reliance

any

such

forward-looking

statements,

which

speak

only

the

date

they

were

made.

Cytyc

disclaims

any

obligation

publicly

update

revise

any

such

statements

reflect

any

change

its

expectations

events,

conditions,

circumstances

which

any

such

statements

may

based,

that

may

affect

the

likelihood

that

actual

results

will

differ

from

those

set

forth

the

forward-looking

statements.

Disclaimer Regarding Forward-Looking

Statements (continued)

Forward-Looking

Statements

Regarding

the

Proposed

Hologic-Cytyc

Transaction

This

presentation

also

includes

forward-looking

statements

about

the

timing

the

completion

the

transaction,

the

anticipated

benefits

the

business

combination

transaction

involving

Hologic

and

Cytyc,

including

future

financial

and

operating

results,

the

expected

permanent

financing

for

the

transaction,

the

combined

company's

plans,

objectives,

expectations

and

intentions

and

other

statements

that

are

not

historical

facts.

Hologic

and

Cytyc

caution

readers

that

any

forward-looking

information

not

guarantee

future

performance

and

that

actual

results

could

differ

materially

from

those

contained

the

forward-looking

information.

These include risks and uncertainties relating to: the ability to obtain regulatory approvals of

the transaction on the proposed terms and schedule; the parties may be unable to complete

the transaction because conditions to the closing of the transaction may not be satisfied; the

risk that the businesses will not be integrated successfully; the transaction may involve

unexpected costs or unexpected liabilities; the risk that the cost savings and any other

synergies from the transaction may not be fully realized or may take longer to realize than

expected; disruption from the transaction making it more difficult to maintain relationships

with customers, employees or suppliers; competition and its effect on pricing, spending,

third-party relationships and revenues; the need to develop new products and adapt to

Disclaimer Regarding Forward-Looking

Statements (continued)

significant

technological

change;

implementation

strategies

for

improving

internal

growth;

use

and

protection

intellectual

property;

dependence

customers'

capital

spending

policies

and

government

funding

policies,

including

third-party

reimbursement;

realization

potential

future

savings

from

new

productivity

initiatives;

general

worldwide

economic

conditions

and

uncertainties;

future

legislative,

regulatory,

tax

changes

well

other

economic,

business

and/or

competitive

factors;

and

the

effect

exchange

rate

fluctuations

international

operations.

addition,

the

transaction

will

require

the

combined

company

obtain

significant

financing.

While

Hologic

has

obtained

commitment

obtain

such

financing,

including

bridge

the

permanent

financing

contemplated

the

presentation,

the

combined

company’s

liquidity

and

results

operations

could

materially

adversely

affected

such

financing

not

available

favorable

terms.

Moreover,

the

substantial

leverage

resulting

from

such

financing

will

subject

the

combined

company’s

business

additional

risks

and

uncertainties.

The

risks

included

above

are

not

exhaustive.

The

annual

reports

Form

10-K,

the

quarterly

reports

Form

10-Q,

current

reports

Form

8-K

and

other

documents

Hologic

and

Cytyc

have

filed

with

the

SEC

contain

additional

factors

that

could

impact

the

combined

company’s

businesses

and

financial

performance.

The

parties

expressly

disclaim

any

obligation

undertaking

release

publicly

any

updates

revisions

any

such

statements

reflect

any

change

the

parties’

expectations

any

change

events,

conditions

circumstances

which

any

such

statement

based.

Important Information for Investors and

Stockholders

Hologic and Cytyc will file a joint proxy statement/prospectus with the SEC in connection

with the proposed merger. HOLOGIC AND CYTYC URGE INVESTORS AND

STOCKHOLDERS TO READ THE JOINT PROXY STATEMENT/PROSPECTUS WHEN

IT BECOMES AVAILABLE AND ANY OTHER RELEVANT DOCUMENTS FILED BY

EITHER PARTY WITH THE SEC BECAUSE THEY WILL CONTAIN IMPORTANT

INFORMATION.

Investors

and

stockholders

will

able

obtain

the

joint

proxy

statement/prospectus

and

other

documents

filed

with

the

SEC

free

charge

the

website

maintained

the

SEC

www.sec.gov.

addition,

documents

filed

with

the

SEC

Hologic

will

available

free

charge

the

investor

relations

portion

the

Hologic

website

www.hologic.com.

Documents

filed

with

the

SEC

Cytyc

will

available

free

charge

the

investor

relations

portion

the

Cytyc

website

www.cytyc.com.

Participants in the Solicitation

Hologic,

and

certain

its

directors

and

executive

officers,

may

deemed

participants

the

solicitation

proxies

from

the

stockholders

Hologic

connection

with

the

merger.

The

names

Hologic’s

directors

and

executive

officers

and

description

their

interests

Hologic

are

set

forth

the

proxy

statement

for

Hologic’s

2006

annual

meeting

stockholders,

which

was

filed

with

the

SEC

January

25,

2007.

Cytyc,

and

certain

its

directors

and

executive

officers,

may

deemed

participants

the

solicitation

proxies

from

its

stockholders

connection

with

the

merger.

The

names

Cytyc’s

directors

and

executive

officers

and

description

their

interests

Cytyc

set

forth

Cytyc’s

Annual

Report

Form

10-K/A

for

the

fiscal

year

ended

December

31,

2006,

which

was

filed

with

the

SEC

April

30,

2007.

Investors

and

stockholders

can

obtain

detailed

information

regarding

the

direct

and

indirect

interests

Hologic’s

and

Cytyc’s

directors

and

executive

officers

the

merger

reading

the

definitive

joint

proxy

statement/prospectus

when

becomes

available.

Use of Non-GAAP Financial Measures

addition

the

financial

measures

prepared

accordance

with

generally

accepted

accounting

principles

(GAAP),

use

the

non-GAAP

financial

measures

"adjusted

EPS"

and

“EBITDA”.

Adjusted

EPS

excludes

the

write-off

and

amortization

acquisition-related

intangible

assets,

and

tax

provisions/benefits

thereto.

EBITDA

defined

net

earnings

(loss)

before

interest,

taxes,

depreciation

and

amortization

expense.

Neither

adjusted

EPS

nor

EBITDA

measure

operating

performance

under

GAAP.

believe

that

the

use

these

non-GAAP

measures

helps

investors

gain

better

understanding

our

core

operating

results

and

future

prospects,

consistent

with

how

management

measures

and

forecasts

our

performance,

especially

when

comparing

such

results

periods

forecasts.

When

analyzing

our

operating

performance,

investors

should

not

consider

these

non-GAAP

measures

substitute

for

net

income

prepared

accordance

with

GAAP.

Growth Objectives and Strategy

Deliver 20+% long-term earnings growth through:

Global organic growth across divisions

Internal research and development

Strategic acquisitions and partnerships

Grow existing businesses resulting in continued

revenue growth and improved PBIT margins

Enhance organizational bench strength by attracting,

motivating, and retaining top talent to support

business needs

GEA Market Opportunity

2006 NovaSure Market Share and Total Procedure Potential

GEA Market Opportunity

2006 NovaSure Market Share and Total Procedure Potential

NS Share

= 62%*

NS Share

= 9%

NS Share

= 3%

Note:US

NovaSure

dollar

equals

69%

1,000,000

2,000,000

3,000,000

4,000,000

5,000,000

6,000,000

7,000,000

8,000,000

2006 - Current GEA

2006- Treatment

Pathway

2006 - Silent

Sufferers

Silent Sufferers

Hormones

Hysterectomy

Rollerball

D&C

GEA

MammoSite

Radiation Therapy

MammoSite

Radiation Therapy

Creating new standard of care

Deliver optimal dose of radiation

to tissue at highest risk of

cancer recurrence

Minimize damage to healthy

tissue

Expanding data supports partial

breast radiation and MammoSite

Clinical trial (5-year data; 43

patients): 0 recurrences

ASBS registry (2-year data;

1,400 patients)

MammoSite

RTS

afterloader

accessories

MammoSite

RTS applicator

50,000

100,000

150,000

200,000

250,000

300,000

MammoSite Market Opportunity

275,221

189,490

131,695

126,002

MammoSite Primary

U.S. Cases of Breast Cancer and DCIS (.4% Incidence, 40+)

Patients Eligible for Breast Conserving Therapy (Excludes >3cm, Size A)

Patients Receiving Breast Conserving Therapy (70%)

Patients Eligible for Mammosite (Excludes women <45, Pathology)

Market Opportunity

Large tumors

70% elect BCT

Surgical

margins or

lymph node

involvement

Cellient

™

Automated Cell Block System

Cellient

™

Automated Cell Block System

Allows individual cells or small tissue samples (<2mm

diameter) to be processed for histological examination

Eliminates operator dependence

Provides standardized, consistent preparations in less

than one hour, and ensures sample chain of custody

Market launch: Second half 2007

Sold by existing lab sales force

Market opportunity up to $200 million worldwide

Domestic Diagnostic Products -

Summary

Domestic Diagnostic Products -

Summary

ThinPrep

Pap Test

Leading test for cervical cancer screening

US opportunity: 50-55 million tests annually

International: >100 million tests

250 million tests since approval

Platform technology

ThinPrep

Imaging System

Advanced computerized imaging

46% ThinPrep

Pap Test slides imaged Q1 2007

FullTerm: The Fetal Fibronectin

Test

Cellient

™

Automated Cell Block System

Automated system to prepare individual cells or small tissue

samples for histological examination

Market launch: Second half 2007

FullTerm: The Fetal Fibronectin

Test

Predictor of preterm birth

Expanded Product Portfolio

Comprehensive Sales Coverage

Ability to Leverage OB/GYN Channel

Significant Cross-Selling Synergies

Enhanced International Presence

Creating a Global Leader in Women’s Healthcare

Market Share Leader in Major Product

Lines

Proven Management Team

Significant Cash Flow Generation

Accretive to Adjusted EPS

Within the

First Full Year After Close

Strategic Rationale

Combined Strengths

Adjusted EPS excludes the write-off and amortization of acquisition-related

intangible assets, and related tax effect.

MultiCare

Stereotactic

Biopsy

Discovery

Osteoporosis

Screening

Selenia

Breast Cancer

Screening

MammoSite

Radiation

Therapy

ThinPrep Pap Test & Imaging System

Cervical Cancer Screening

NovaSure

Endometrial

Ablation

Adiana

Contraception

FullTerm

Adeza

Preterm Labor

Best-in-Class Solutions

Women’s Healthcare

Suros

Biopsy Systems

Comprehensive Women’s Healthcare Platform

Solutions for Major Women’s Healthcare Issues

Helica

Unpenetrated

1 in 3

Gestiva

International

ThinPrep

Imaging System

International

Tomosynthesis

Suros Celero

Additional

Opportunities

Adiana

FullTerm

Fetal

Fibronectin

Discovery

Sahara

NovaSure

ThinPrep

Pap Test

Selenia

MultiCare

Suros ATEC

MammoSite

Combined

Offering

High

Medium

Low

High

Medium

High

Market Growth

$100M

$1B+

$400M

$110M

$2.5B+

$550M

$1B

U.S. Market Size

1 in 4

1 in 2

Pregnancies

1 in 2

1 in 5

1 in 138

1 in 8

U.S. Women

Affected

Endometriosis

Permanent

Contraception

Preterm

Labor

Osteoporosis

Menorrhagia

Cervical

Cancer

Breast

Cancer

International

U.S. Market

Position

International

Source: Market research and company estimates.

Multiple platforms to enhance top and bottom line growth

Increased scale through diversification of revenue and

strong margin profile

Enhanced cash flow; LQA EBITDA of ~$436M

Revenue and cost synergy opportunities

Estimated

than

$0.10

accretive

adjusted

EPS

within

the

first

full

year

after

close,

significantly

accretive

thereafter

Rapid debt repayment, incremental earnings growth

Financial Rationale

Adjusted EPS excludes the write-off and amortization of acquisition-related

intangible assets, and related tax effect.

Creating a Global Leader in Women’s Healthcare

Comprehensive Women’s Healthcare Product Portfolio

–

Complementary best-in-class technologies

Expanded Commercial Capabilities

–

Expansive U.S. sales channel coverage

–

Enhanced presence in key international markets

–

Platform for entry into new markets

Opportunity to offer Integrated Solutions

–

Screening

–

Diagnostics

–

Therapeutics